The clinical effect of Pingxiao capsule as an adjuvant chemotherapy in the treatment of patients with stage III-IV laryngeal cancer and its influence on angiogenesis and tumor markers

Abstract

Objective To explore the clinical effects of Pingxiao capsule as an adjuvant chemotherapy in the treatment of patients with stage III-IV laryngeal cancer and its influence on angiogenesis and tumor markers. Methods A total of 66 patients with stage III-IV laryngeal cancer treated at our hospital from August 2017 to April 2019 were selected as the study subjects, and they were divided into observation group and control group  according to random number table method. The control group was treated with TPF regimen, while the observation group was treated with Pingxiao capsule on the basis of the control group. The objective remission rate,vascular endothelial growth factor, matrix metalloproteinase-9 , carbohydrate antigen 19-9, cytokeratin 19 fragment , squamous cell carcinoma associated antigen level and the incidence of adverse reactions were compared between the two groups. Results The ORR of the observation group was significantly higher than that of the control group . After treatment, the levels of VEGF and MMP-9 in the observation group were greatly lower than those before treatment and in the control group, and the levels of CA19-9, CYFRA21-1 and SCC-Ag in the observation group were noticeably lower than those before treatment and the control group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Pingxiao capsule as an adjuvant treatment to chemotherapy showed a high clinical effect in the treatment of stage III-IV laryngeal cancer patients, and it can inhibit angiogenesis factors, reduce the levels of body tumor markers and the occurrence of adverse reactions.